Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis

Clinical and Experimental Gastroenterology

Volumn 7, Issue 1, 2014, Pages 13-23

  Gupta, Ram ^a   Chaudhary, Anita R ^a   Shah, Binita N ^a   Jadhav, Avinash V ^a   Zambad, Shitalkumar P ^a   Gupta, Ramesh Chandra ^a   Deshpande, Shailesh ^a   Chauthaiwale, Vijay ^a   Dutt, Chaitanya ^a  

^a Torrent Pharmaceuticals Ltd   (India)

Author keywords

HIF activation; Hypoxia inducible factor; IBD

Indexed keywords

EID: 84893356598     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S51923     Document Type: Article

References (28)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785-1794.
2. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066-2078.
3. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005;54(10): 14811-11491.
4. Hindryckx P, Laukens D, De Vos M. Boosting the hypoxia-induced adaptive response in inflammatory bowel disease: a novel concept of treatment. Inflamm Bowel Dis. 2011;17(9):2019-2022.
5. Cummins EP, Doherty GA, Taylor CT. Hydroxylases as therapeutic targets in inflammatory bowel disease. Lab Invest. 2013;93(4): 378-383.
6. Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6(4):607-620.
7. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619-1635.
8. Wilson BS, Lönnfors S, Vermeire S, et al. The True Impact of IBD: A European Crohn's and Ulcerative Colitis Patient Life. IMPACT Survey 2010-2011. Available from: http://efcca-solutions.net/media/jointhefight/ImpactReport.pdf. Accessed June 4, 2013.
9. Colgan SP, Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol. 2010;7(5):281-287.
10. Glover LE, Colgan SP. Hypoxia and metabolic factors that influence inflammatory bowel disease pathogenesis. Gastroenterology. 2011;140(6):1748-1755.
11. Jamadarkhana P, Chaudhary A, Chhipa L, et al. Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury. Am J Nephrol. 2012;36(3):208-218.
12. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(3):2151-2156.
13. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, Colgan SP. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology. 2008;134(1):145-155.
14. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114(8):1098-1106.
15. Committee for the Purpose of Control and Supervision on Experiments on Animals. CPCSEA Guidelines for Laboratory Animal Facility. Ind J Pharmacol. 2003;35(4):257-274.
16. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324(1): 23-33.
17. Zhang DK, Yu JJ, Li YM, et al. A Picrorhiza kurroa derivative, picroliv, attenuates the development of dextran-sulfate-sodium-induced colitis in mice. Mediators Inflamm. 2012;2012:751629.
18. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96(3):795-803.
19. Luna LG. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. 3rd ed. New York: McGraw-Hill; 1968.
20. Kitajima S, Takuma S, Morimoto M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim. 2000;49(1):9-15.
21. Murano N, Murano M, Ishida K, et al. Therapeutic effect of SHI-219, a novel water soluble prodrug of EG626 (phtalazinol), on mouse dextran sodium sulfate-induced colitis. Bull Osaka Med Coll. 2006;52(2): 69-79.
22. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol. 2000;19(1):51-62.
23. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114(3):385-391.
24. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98(3): 694-702.
25. Xue H, Sufit AJ, Wischmeyer PE. Glutamine therapy improves outcome of in vitro and in vivo experimental colitis models. JPEN J Parenter Enteral Nutr. 2011;35(2):188-197.
26. Hu S, Zhu X, Triggs JR, et al. Inflammation-induced, 3′UTR-dependent translational inhibition of Hsp70 mRNA impairs intestinal homeostasis. Am J Physiol Gastrointest Liver Physiol. 2009;296(5): G1003-G1011.
27. Hu S, Ciancio MJ, Lahav M, et al. Translational inhibition of colonic epithelial heat shock proteins by IFN-gamma and TNF-alpha in intestinal inflammation. Gastroenterology. 2007;133(6):1893-1904.
28. Liedel JL, Guo Y, Yu Y, et al. Mother's milk-induced Hsp70 expression preserves intestinal epithelial barrier function in an immature rat pup model. Pediatr Res. 2011;69(5 Pt 1):395-400.